Sawyer & Company Inc Trims Stake in Johnson & Johnson (NYSE:JNJ)

Sawyer & Company Inc lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,476 shares of the company’s stock after selling 906 shares during the quarter. Johnson & Johnson comprises 1.7% of Sawyer & Company Inc’s portfolio, making the stock its 17th largest position. Sawyer & Company Inc’s holdings in Johnson & Johnson were worth $3,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Hibernia Wealth Partners LLC bought a new stake in Johnson & Johnson during the third quarter worth about $27,000. FNY Investment Advisers LLC bought a new stake in Johnson & Johnson during the third quarter worth about $37,000. Tower View Wealth Management LLC boosted its stake in Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares in the last quarter. Creative Capital Management Investments LLC lifted its stake in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Finally, UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $157.96 on Thursday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a market cap of $380.65 billion, a price-to-earnings ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The business has a 50-day moving average price of $158.76 and a 200-day moving average price of $156.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.35 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were given a dividend of $1.19 per share. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.